Renaissance Capital logo

Impel NeuroPharma Priced, Nasdaq: IMPL

Late-stage developer of intranasal drug formulations for migraines and CNS diseases.

Industry: Health Care

First Day Return: 0.0%

Industry: Health Care

We are a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS. Our strategy is to pair our proprietary Precision Olfactory Delivery upper nasal delivery technology with well-established therapeutics or other therapeutics where rapid vascular absorption is preferred to drive therapeutic benefit, improve patient outcomes, reduce drug development risk and expand the commercial opportunity within our target diseases. Since 2016, we have identified and advanced multiple product candidates, including TRUDHESATM (INP104) for the acute treatment of migraine and INP105 for the acute treatment of agitation and aggression in patients with Autism Spectrum Disorder. In November 2020, we submitted an NDA for TRUDHESA, for the acute treatment of migraine headaches with or without aura in adult patients. The FDA has filed and accepted the NDA for review and established a Prescription Drug User Fee Act goal date of September 6, 2021.
more less

Impel NeuroPharma (IMPL) Performance